Topics

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989

2020-01-02 05:55:54 | BioPortfolio

Summary

The purpose of the study is to evaluate the single-dose pharmacokinetic (PK) of JNJ-73763976 and JNJ-73763924 following a subcutaneous (SC) injection of JNJ-73763989 (JNJ-3989) in participants with liver cirrhosis and various degrees of impaired hepatic function when compared with healthy participants with normal hepatic function and no liver cirrhosis.

Study Design

Conditions

Hepatic Impairment

Intervention

JNJ-73763989

Location

CRS Clinical Research Services Kiel GmbH
Kiel
Germany
24105

Status

Not yet recruiting

Source

Janssen Sciences Ireland UC

Results (where available)

View Results

Links

Published on BioPortfolio: 2020-01-02T05:55:54-0500

Clinical Trials [1049 Associated Clinical Trials listed on BioPortfolio]

A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

The purpose of this study is to establish the dose-response relationship for antiviral activity of 3 dose levels of JNJ-73763989+nucleos(t)ide analog (NA) and to evaluate the efficacy of c...

A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

The purpose of this study is to evaluate the efficacy of 48-week study intervention with JNJ-73763989+JNJ-56136379+nucleos(t)ide analog (NA) regimen compared to NA alone assessed by HBsAg ...

A Study of JNJ-73763989 in Healthy Japanese Adult Participants

The purpose of this study is to investigate the pharmacokinetics, safety, and tolerability of JNJ-73763989 in healthy Japanese adult participants following single-dose subcutaneous adminis...

Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects

This is a Phase 1, single-centre, open-label, parallel-group study in subjects with moderate hepatic impairment and subjects with normal hepatic function. Child-Pugh (CP) scoring will be u...

Hepatic Impairment Study in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

This is a study to characterize the pharmacokinetics, safety and tolerability of KD025 and KD025 metabolites in subjects with mild, moderate or severe hepatic impairment compared to health...

PubMed Articles [3686 Associated PubMed Articles listed on BioPortfolio]

Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment.

Dotinurad is a novel, selective urate reabsorption inhibitor, which reduces serum uric acid levels by inhibiting the urate transporter 1 (URAT1). We compared the pharmacokinetics (PK), pharmacodynamic...

Minimal impact of hepatic- and renal- impairment on plasma protein binding of lenvatinib, and identification of its major plasma binding protein.

Plasma protein binding (PPB) can be different depending on the status of hepatic or renal functions. In this study, PPB of lenvatinib was determined using equilibrium dialysis in plasma from healthy v...

Rosuvastatin improves olanzapine's effects on behavioral impairment and hippocampal, hepatic and metabolic damages in isolated reared male rats.

Schizophrenia is a chronic, disabling neurological illness. This study investigated the effect of rosuvastatin (RSU) addition to the antipsychotic drug: olanzapine (OLZ) in treatment of post-weaning i...

The signaling pathways implicated in impairment of hepatic autophagy in glycogen storage disease type Ia.

Glucose-6-phosphatase-α (G6Pase-α or G6PC) deficiency in glycogen storage disease type-Ia (GSD-Ia) leads to impaired hepatic autophagy, a recycling process important for cellular metabolism and home...

Management of hepatic encephalopathy in Germany: a survey among physicians.

 Hepatic encephalopathy (HE) is a severe complication of liver cirrhosis with impairment of quality of life and prognosis. Management patterns among physicians have not been investigated yet.

Medical and Biotech [MESH] Definitions

Cholangiocarcinoma arising near or at the confluence of the right and left hepatic ducts (COMMON HEPATIC DUCT). These tumors are generally small, sharply localized, and seldom metastasizing.

A group of metabolic diseases due to deficiency of one of a number of LIVER enzymes in the biosynthetic pathway of HEME. They are characterized by the accumulation and increased excretion of PORPHYRINS or its precursors. Clinical features include neurological symptoms (PORPHYRIA, ACUTE INTERMITTENT), cutaneous lesions due to photosensitivity (PORPHYRIA CUTANEA TARDA), or both (HEREDITARY COPROPORPHYRIA). Hepatic porphyrias can be hereditary or acquired as a result of toxicity to the hepatic tissues.

A class of nongenotoxic CARCINOGENS that induce the production of hepatic PEROXISOMES and induce hepatic neoplasms after long-term administration.

A rare autosomal recessive disorder of the urea cycle. It is caused by a deficiency of the hepatic enzyme ARGINASE. Arginine is elevated in the blood and cerebrospinal fluid, and periodic HYPERAMMONEMIA may occur. Disease onset is usually in infancy or early childhood. Clinical manifestations include seizures, microcephaly, progressive mental impairment, hypotonia, ataxia, spastic diplegia, and quadriparesis. (From Hum Genet 1993 Mar;91(1):1-5; Menkes, Textbook of Child Neurology, 5th ed, p51)

Professionals skilled at diagnostic testing of hearing, HEARING IMPAIRMENT, and CORRECTION OF HEARING IMPAIRMENT by non-medical or non-surgical means.

More From BioPortfolio on "A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989"

Quick Search

Relevant Topic

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...


Searches Linking to this Trial